Biotechnology
Foresee Pharmaceuticals Announces NDA for CAMCEVI(TM) 42MG Accepted for Review by the FDA
TAIPEI, Oct. 8, 2020 /PRNewswire/ -- Foresee Pharmaceuticals Co., Ltd. (6576.TWO) ("Foresee") announced today that the 505(b)(2) New Drug Application (NDA) for FP-001 LMIS 50mg, or CAMCEVI™ 42MG, a ready-to-use 6-month depot formulation of leuprolide mesylate, has been accepted for review by the ...
2020-10-09 06:39
1899
EB Research Partnership and EB Research Foundation Come Together as Largest Global Organization Advancing Research for Epidermolysis Bullosa
As the leading EB research funders worldwide, the group will combine to leverage EBRP's innovative business model to accelerate treatments and cures NEW YORK and MELBOURNE, Australia, Oct. 9, 2020 /PRNewswire/ -- EB Research Partnership (EBRP), based inNew York, and EB Research Foundation (EBRF) ...
2020-10-08 21:00
2573
Nagase R&D Center Increases Productivity of Rare Amino Acid "Ergothioneine" 1000-fold: Highest Production Efficiency Reported Using "Smart Cell" Technology
TOKYO, Oct. 7, 2020 /PRNewswire/ -- The Nagase R&D Center, the research and development arm of NAGASE & CO., LTD. based inTokyo, has been developing fermentative production technology for ergothioneine (EGT) (*1) and researching EGT's functions. Using revolutionary biotechnology developed as part...
2020-10-07 14:00
1941
CARsgen Therapeutics Granted Orphan Drug Designation by the US FDA for CT041 CLDN18.2 CAR-T Cells for the Treatment of Gastric and Gastroesophageal Junction Cancers
SHANGHAI, Oct. 5, 2020 /PRNewswire/ -- CARsgen Therapeutics Co., Ltd., a clinical-stage biopharmaceutical company, today announced thatthe United States (US) Food and Drug Administration (FDA) has granted orphan drug designation to one of CARsgen's first-in-class drug candidates, CT041, for the t...
2020-10-05 18:00
4687
Happiness Biotech Announced Receipt of FDA Registration For Its Hand Sanitizer
NANPING, China, Oct. 1, 2020 /PRNewswire/ -- Happiness Biotech Group Limited (the "Company" or Nasdaq: HAPP), an innovativeChina-based nutraceutical and dietary supplements producer, announced today that the Company's hand sanitizer products have been registered with U.S. Food and Drug Administra...
2020-10-01 22:00
12879
TaiGen Biotechnology Out-Licensed Taigexyn (Nemonoxacin) to Luminarie Canada for Canada, Australia and New Zealand
TAIPEI, Sept. 30, 2020 /PRNewswire/ -- TaiGen Biotechnology Company, Limited ("TaiGen")(Taiwan: 4157) today announced that they have signed an exclusive licensing agreement with Luminarie Canada Inc. ("Luminarie"), a leading Canadian pharmaceutical company, to develop and commercialize Taigexyn® ...
2020-09-30 15:51
1651
World's first clinical trial of non-viral PD1 specific targeted CAR T therapy achieves great breakthroughs
SHANGHAI, Sept. 28, 2020 /PRNewswire/ -- On September 25, 2020, BIORAY LABORATORIES Inc. ("Bioraylab"), a company specialized in gene therapy and cell drug R&D, announced for the first time that clinical trials of non-viral PD1 specific targeted CAR T therapy in relapsed/refractory B-cell non-Hod...
2020-09-28 19:00
1475
ILIAS Biologics Closes $20.6 Million Series B Financing
DAEJEON, South Korea, Sept. 28, 2020 /PRNewswire/ -- ILIAS Biologics Inc. (the "Company" or "ILIAS"), a leading exosome-based therapeutics company, announced today that the Company has completed a Series B financing round of$20.6 million inSouth Korea. The initial investors from the Series A rou...
2020-09-28 19:00
1590
Carmine Therapeutics named as one of FierceBiotech's "Fierce 15" Biotech Companies of 2020
CAMBRIDGE, Mass., Sept. 28, 2020 /PRNewswire/ -- Carmine Therapeutics announced today that it has been named by FierceBiotech as one of 2020's Fierce 15 biotechnology companies, designating it as one of the most promising private biotechnology companies in the industry. The 2020 Fierce 15 com...
2020-09-28 18:00
1305
Neurophth Therapeutics' Treatment of Leber's Hereditary Optic Neuropathy Gene Therapy NR082 was Granted Orphan Drug Designation by U.S. FDA
NEWARK, Del., Sept. 24, 2020 /PRNewswire/ -- Neurophth Therapeutics, Inc., (hereinafter referred to as "Neurophth") today announced that its leading candidate, NR082 (rAAV2-ND4, NFS-01 project), was granted an orphan drug designation (ODD) by the U.S. FDA for the treatment of Leber's Hereditary O...
2020-09-25 10:37
2089
KYAN Therapeutics Exclusively Licenses Small Molecule HDAC Inhibitors for AI-Powered Cancer Drug Development
SINGAPORE, Sept. 24, 2020 /PRNewswire/ -- KYAN Therapeutics, Inc. ("KYAN"), a frontier biotech company with a novel drug-dose combination optimizing platform, Optim.AI, has entered into an exclusive license agreement with Georgetown University for novel selective Class II HDAC inhibitors. KYAN has...
2020-09-24 17:12
1580
ImmVira Announces US$10 million Strategic Series B Plus Financing with SIIC Capital
SHENZHEN and SHANGHAI, Sept.23, 2020 /PRNewswire/ -- ImmVira Group Company, a biotechnology company focused on the development of new generation oncolytic viruses as potential cancer therapeutics today announced signing ofUS$10 million Series B Plus strategic financing. This round of financing wi...
2020-09-24 00:09
2071
Minoryx Therapeutics and Sperogenix Therapeutics enter into an exclusive license agreement to develop and commercialize leriglitazone in mainland China, Hong Kong and Macau
* Minoryx will receive an upfront and milestone payments of up to $78 million , as well as double digit royalties on annual net sales * Sperogenix will receive exclusive rights to develop and commercialize leriglitazone for the treatment of X-linked adrenoleukodystrophy (X-ALD), a rare life-th...
2020-09-23 15:00
1428
Cosmo PR and HekaBio Announce Strategic Partnership and Investment in HekaBio
TOKYO, Sept. 22, 2020 /PRNewswire/ -- HekaBio K.K. (hereafter: HekaBio) and Cosmo Public Relations Corporation (hereafter:Cosmo) have announced that Cosmo has made an investment in HekaBio and that the companies have entered into a strategic partnership to increase awareness of and accessibility ...
2020-09-23 09:00
1853
Samsung Biologics and AstraZeneca forge strategic manufacturing partnership for global supply
INCHEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) and AstraZeneca announced a long-term supply agreement, valued at approximately $330.8 million. Under this agreement, Samsung Biologics will provide large-scale commercial manufacturing for drug substance in its Pla...
2020-09-22 07:00
12623
PharmAbcine expands partnership with Samsung Biologics for PMC-403
DAEJEON, South Korea, Sept. 21, 2020 /PRNewswire/ -- PharmAbcine Inc. (KOSDAQ: 208340ks) entered into a strategic partnership with Samsung Biologics (KRX: 207940.KS) for the development and manufacturing of PMC-403 pipeline, the next generation therapeutic antibody candidate to treat neovascular ...
2020-09-21 20:00
1587
Expanding Their Existing Strategic Collaboration, GenScript ProBio Licensed Global Rights to Develop and Commercialize a SMAB Bispecific Antibody Molecule to REMD Biotherapeutics Inc.
NANJING, China, Sept. 17, 2020 /PRNewswire/ -- On September 16th, 2020, GenScript ProBio and REMD Biotherapeutics Inc. (REMD) announced that REMD has licensed a bispecific antibody derived from the Single-domain antibody fused to Monoclonal Ab (SMAB) platform developed by GenScript ProBio. REMD i...
2020-09-17 22:00
2069
Samsung Biologics signs development agreement with Panolos for solid tumor treatment
INCHEON, South Korea, Sept. 16, 2020 /PRNewswire/ -- Samsung Biologics (207940.KS) has entered into a service agreement with Panolos Bioscience to develop PB101, an Fc-fusion protein intended to treat solid tumors. Under this agreement, Samsung Biologics will provide a full scope of its developm...
2020-09-17 08:43
2421
Less is more: Novel algorithm automatically removes poor-quality data to improve AI scalability
SAN FRANCISCO, Sept. 15, 2020 /PRNewswire/ -- AI Healthcare company Presagen
has developed a novel technique that is able to automatically clean
poor-quality data needed to train scalable and reliable Artificial Intelligence
products.
2020-09-16 22:50
1786
Transcenta Successfully Scaled up the Continuous Perfusion Process and Completed GMP Manufacturing of a Novel Bispecific Antibody for Cancer Immunotherapy
SUZHOU, China and HANGZHOU, China, Sept. 15, 2020 /PRNewswire/ -- Transcenta, a global biotherapeutics company, today announced success in scaling up the continuous perfusion process to 200L and completion of GMP production of a bispecific antibody for a Phase 1 clinical study. "This is an impo...
2020-09-15 23:00
1581
Week's Top Stories
Most Reposted
LINKDOOD Breaks Language Barriers, Ushering a New Era for Cross-Border Romance
[Picked up by 326 media titles]
2024-04-29 06:00
Multiple achievements made in China-Hungary BRI conference
[Picked up by 309 media titles]
2024-05-03 06:59
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
[Picked up by 293 media titles]
2024-04-30 10:11
Xinhua president, Hungarian economy minister vow to bolster media cooperation
[Picked up by 280 media titles]
2024-05-03 06:25Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
[Picked up by 269 media titles]
2024-04-28 09:39
Most Read
Dow showcases circular and innovative materials science solutions and industry collaborations at Chinaplas 2024
2024-04-30 10:11
2999
Ferretti's Dazzling Presence at the 2024 Singapore Yachting Festival: Showcasing Evolving Trends in Luxury Yachting
2024-04-28 15:02
2966
Scienjoy Holding Corporation Reports Fiscal Year 2023 Financial Results
2024-04-27 04:30
2965
Puyuan Fashion Resort 2024: A Grand Unveiling of Global Trends and Local Heritage
2024-04-28 09:39
2848